Lexaria Bioscience Corp. Annual report pursuant to Section 13 and 15(d)

Marketable Securities (Details) - USD ($)	12 Months Ended
Marketable Securities (Details) - USD ($)	Aug. 31, 2022	Aug. 31, 2021	Aug. 31, 2020
Common Stock [Member]
Cost Basis	$ 278,107	$ 980,775
Unrealized Gains	118,195	6,802
Unrealized Losses	(882,809)	(190,665)
Total [Member]
Cost Basis	1,315,132	1,037,025	$ 56,250
Unrealized Gains	134,438	16,243	9,441
Unrealized Losses	(1,102,236)	(219,427)	(28,762)
Total	$ 347,335	$ 833,841	$ 19,321